{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T02:40:21Z","timestamp":1733280021663,"version":"3.30.1"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.lungcan.2024.108024","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T17:05:21Z","timestamp":1730999121000},"page":"108024","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["NOTCH and PTP4A3 alterations emerge as novel predictive biomarkers and potential therapeutic targets in pleural mesothelioma"],"prefix":"10.1016","volume":"198","author":[{"given":"Mariacarmela","family":"Santarpia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Aliprandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Calogera","family":"Claudia Spagnolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Avan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0817-3400","authenticated-orcid":false,"given":"Rafael","family":"Rosell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Andrea Zucali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Giovannetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.lungcan.2024.108024_b0005","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.lungcan.2024.108024_b0010","doi-asserted-by":"crossref","first-page":"1158416","DOI":"10.3389\/fonc.2023.1158416","article-title":"Editorial: Advances in malignant pleural mesothelioma: Diagnosis, treatment, and molecular mechanisms","volume":"13","author":"Mastromarino","year":"2023","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2024.108024_b0015","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/sonc.2002.30227","article-title":"The pathogenesis of mesothelioma","volume":"29","author":"Carbone","year":"2002","journal-title":"Semin. Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2024.108024_b0020","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.jtho.2018.08.2036","article-title":"Current and future management of malignant mesothelioma: A consensus report from the national cancer institute thoracic malignancy steering committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation","volume":"13","author":"Tsao","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2024.108024_b0025","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1097\/JTO.0000000000000506","article-title":"The presence of asbestos in the natural environment is likely related to mesothelioma in young individuals and women from southern Nevada","volume":"10","author":"Baumann","year":"2015","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2024.108024_b0030","doi-asserted-by":"crossref","first-page":"89","DOI":"10.5858\/arpa.2017-0124-RA","article-title":"Guidelines for pathologic diagnosis of malignant mesothelioma 2017 update of the consensus statement from the international mesothelioma interest group","volume":"142","author":"Husain","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"17\u201318","key":"10.1016\/j.lungcan.2024.108024_b0035","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s00508-016-1080-z","article-title":"Austrian Mesothelioma Interest, Management of malignant pleural mesothelioma - part 1: epidemiology, diagnosis, and staging : Consensus of the Austrian Mesothelioma Interest Group (AMIG)","volume":"128","author":"Geltner","year":"2016","journal-title":"Wien. Klin. Wochenschr."},{"issue":"4","key":"10.1016\/j.lungcan.2024.108024_b0040","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jtho.2015.12.108","article-title":"A novel clinical prediction model for prognosis in malignant pleural mesothelioma using decision tree analysis","volume":"11","author":"Brims","year":"2016","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2024.108024_b0045","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jtho.2015.10.003","article-title":"Contemporary analysis of prognostic factors in patients with unresectable malignant pleural mesothelioma","volume":"11","author":"Bille","year":"2016","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2024.108024_b0050","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jtho.2021.12.014","article-title":"The 2021 WHO classification of tumors of the pleura: advances since the 2015 classification","volume":"17","author":"Sauter","year":"2022","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2024.108024_b0055","doi-asserted-by":"crossref","first-page":"72","DOI":"10.6004\/jnccn.2024.0014","article-title":"Insights: Mesothelioma: Pleural, Version 1.2024","volume":"22","author":"Stevenson","year":"2024","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"6","key":"10.1016\/j.lungcan.2024.108024_b0060","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1200\/JCO.21.01567","article-title":"New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options","volume":"40","author":"Tsao","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"10272","key":"10.1016\/j.lungcan.2024.108024_b0065","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.lungcan.2024.108024_b0070","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/j.jtho.2018.08.001","article-title":"Surgery in Malignant Pleural Mesothelioma","volume":"13","author":"Bueno","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2024.108024_b0075","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.jtcvs.2014.10.128","article-title":"Updated patterns of failure after multimodality therapy for malignant pleural mesothelioma","volume":"149","author":"Baldini","year":"2015","journal-title":"J. Thorac. Cardiovasc. Surg."},{"issue":"12","key":"10.1016\/j.lungcan.2024.108024_b0080","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative Molecular Characterization of Malignant Pleural Mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov."},{"issue":"4","key":"10.1016\/j.lungcan.2024.108024_b0085","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat. Genet."},{"issue":"10","key":"10.1016\/j.lungcan.2024.108024_b0090","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19103056","article-title":"Genomic deletion of BAP1 and CDKN2A are useful markers for quality control of malignant pleural mesothelioma (MPM) primary cultures","volume":"19","author":"Sarun","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"23","key":"10.1016\/j.lungcan.2024.108024_b0095","doi-asserted-by":"crossref","first-page":"9678","DOI":"10.1158\/0008-5472.CAN-08-0969","article-title":"Opposite effects of Notch-1 and Notch-2 on mesothelioma cell survival under hypoxia are exerted through the Akt pathway","volume":"68","author":"Graziani","year":"2008","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.lungcan.2024.108024_b0100","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/17512433.2022.2074835","article-title":"Splicing deregulation, microRNA and notch aberrations: fighting the three-headed dog to overcome drug resistance in malignant mesothelioma","volume":"15","author":"Anobile","year":"2022","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.lungcan.2024.108024_b0105","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3389\/fonc.2018.00091","article-title":"New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma","volume":"8","author":"Rossini","year":"2018","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2024.108024_b0110","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/sj.onc.1206097","article-title":"Notch-1 induction, a novel activity of SV40 required for growth of SV40-transformed human mesothelial cells","volume":"22","author":"Bocchetta","year":"2003","journal-title":"Oncogene"},{"issue":"5415","key":"10.1016\/j.lungcan.2024.108024_b0115","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1126\/science.284.5415.770","article-title":"Notch signaling: cell fate control and signal integration in development","volume":"284","author":"Artavanis-Tsakonas","year":"1999","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.lungcan.2024.108024_b0120","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41392-022-00934-y","article-title":"Notch signaling pathway: architecture, disease, and therapeutics","volume":"7","author":"Zhou","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.lungcan.2024.108024_b0125","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.3389\/fimmu.2020.01958","article-title":"Specific Targeting of Notch Ligand-Receptor Interactions to Modulate Immune Responses: A Review of Clinical and Preclinical Findings","volume":"11","author":"Goruganthu","year":"2020","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.lungcan.2024.108024_b0130","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1242\/dev.01074","article-title":"Notch signaling: control of cell communication and cell fate","volume":"131","author":"Lai","year":"2004","journal-title":"Development"},{"issue":"1","key":"10.1016\/j.lungcan.2024.108024_b0135","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1083\/jcb.200310098","article-title":"Monoubiquitination and endocytosis direct gamma-secretase cleavage of activated Notch receptor","volume":"166","author":"Gupta-Rossi","year":"2004","journal-title":"J. Cell Biol."},{"issue":"4","key":"10.1016\/j.lungcan.2024.108024_b0140","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1158\/1078-0432.CCR-05-2570","article-title":"Notch signaling","volume":"12","author":"Miele","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.lungcan.2024.108024_b0145","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1006\/bbrc.2000.3354","article-title":"Comparative analysis of the human and mouse Hey1 promoter: Hey genes are new Notch target genes","volume":"275","author":"Maier","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"17","key":"10.1016\/j.lungcan.2024.108024_b0150","doi-asserted-by":"crossref","first-page":"5925","DOI":"10.1128\/MCB.21.17.5925-5934.2001","article-title":"Induction of cyclin D1 transcription and CDK2 activity by Notch(ic): implication for cell cycle disruption in transformation by Notch(ic)","volume":"21","author":"Ronchini","year":"2001","journal-title":"Mol. Cell Biol."},{"issue":"8","key":"10.1016\/j.lungcan.2024.108024_b0155","doi-asserted-by":"crossref","first-page":"4458","DOI":"10.4049\/jimmunol.167.8.4458","article-title":"Notch-1 regulates NF-kappaB activity in hemopoietic progenitor cells","volume":"167","author":"Cheng","year":"2001","journal-title":"J. Immunol."},{"issue":"15","key":"10.1016\/j.lungcan.2024.108024_b0160","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1101\/gad.1450406","article-title":"c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia\/lymphoma","volume":"20","author":"Weng","year":"2006","journal-title":"Genes Dev."},{"key":"10.1016\/j.lungcan.2024.108024_b0165","doi-asserted-by":"crossref","first-page":"1078768","DOI":"10.3389\/fonc.2023.1078768","article-title":"Notch signaling, hypoxia, and cancer","volume":"13","author":"Guo","year":"2023","journal-title":"Front. Oncol."},{"issue":"19","key":"10.1016\/j.lungcan.2024.108024_b0170","doi-asserted-by":"crossref","first-page":"6854","DOI":"10.1158\/0008-5472.CAN-04-2500","article-title":"JAGGED1 expression is associated with prostate cancer metastasis and recurrence","volume":"64","author":"Santagata","year":"2004","journal-title":"Cancer Res."},{"issue":"18","key":"10.1016\/j.lungcan.2024.108024_b0175","doi-asserted-by":"crossref","first-page":"8530","DOI":"10.1158\/0008-5472.CAN-05-1069","article-title":"High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival","volume":"65","author":"Reedijk","year":"2005","journal-title":"Cancer Res."},{"issue":"14","key":"10.1016\/j.lungcan.2024.108024_b0180","doi-asserted-by":"crossref","first-page":"6414","DOI":"10.1073\/pnas.92.14.6414","article-title":"Alterations in Notch signaling in neoplastic lesions of the human cervix","volume":"92","author":"Zagouras","year":"1995","journal-title":"PNAS"},{"issue":"3","key":"10.1016\/j.lungcan.2024.108024_b0185","first-page":"665","article-title":"Transendothelial function of human metastatic melanoma cells: role of the microenvironment in cell-fate determination","volume":"62","author":"Hendrix","year":"2002","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.lungcan.2024.108024_b0190","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1158\/0008-5472.CAN-20-2612","article-title":"SCIRT lncRNA restrains tumorigenesis by opposing transcriptional programs of tumor-initiating cells","volume":"81","author":"Zagorac","year":"2021","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.lungcan.2024.108024_b0195","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1084\/jem.20110921","article-title":"Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation","volume":"208","author":"Fabbri","year":"2011","journal-title":"J. Exp. Med."},{"issue":"9","key":"10.1016\/j.lungcan.2024.108024_b0200","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1084\/jem.20120910","article-title":"Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma","volume":"209","author":"Kiel","year":"2012","journal-title":"J. Exp. Med."},{"issue":"12","key":"10.1016\/j.lungcan.2024.108024_b0205","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1182\/blood-2005-01-0355","article-title":"Notch signaling is a potent inducer of growth arrest and apoptosis in a wide range of B-cell malignancies","volume":"106","author":"Zweidler-McKay","year":"2005","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.lungcan.2024.108024_b0210","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1084\/jem.20110198","article-title":"Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway","volume":"208","author":"Viatour","year":"2011","journal-title":"J. Exp. Med."},{"issue":"7563","key":"10.1016\/j.lungcan.2024.108024_b0215","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature14664","article-title":"Comprehensive genomic profiles of small cell lung cancer","volume":"524","author":"George","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.lungcan.2024.108024_b0220","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3389\/fonc.2016.00094","article-title":"Notch signaling in neuroendocrine tumors","volume":"6","author":"Crabtree","year":"2016","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lungcan.2024.108024_b0225","doi-asserted-by":"crossref","first-page":"5","DOI":"10.21037\/sci.2018.02.02","article-title":"Targeting Notch signalling pathway of cancer stem cells","volume":"5","author":"Venkatesh","year":"2018","journal-title":"Stem Cell Investig"},{"issue":"8","key":"10.1016\/j.lungcan.2024.108024_b0230","doi-asserted-by":"crossref","DOI":"10.3390\/cells9081879","article-title":"Cancer stem cells, quo vadis? The notch signaling pathway in tumor initiation and progression","volume":"9","author":"Meisel","year":"2020","journal-title":"Cells"},{"issue":"9","key":"10.1016\/j.lungcan.2024.108024_b0235","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.4252\/wjsc.v7.i9.1185","article-title":"Therapies targeting cancer stem cells: Current trends and future challenges","volume":"7","author":"Dragu","year":"2015","journal-title":"World J. Stem Cells"},{"issue":"2","key":"10.1016\/j.lungcan.2024.108024_b0240","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.pharmthera.2013.02.003","article-title":"Notch inhibitors for cancer treatment","volume":"139","author":"Espinoza","year":"2013","journal-title":"Pharmacol. Ther."},{"issue":"7","key":"10.1016\/j.lungcan.2024.108024_b0245","doi-asserted-by":"crossref","first-page":"824","DOI":"10.2174\/1389450116666150804110714","article-title":"Molecular pharmacology of malignant pleural mesothelioma: challenges and perspectives from preclinical and clinical studies","volume":"17","author":"Thellung","year":"2016","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.lungcan.2024.108024_b0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103698","article-title":"The application of cancer stem cell model in malignant mesothelioma","volume":"174","author":"Bronte","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"2","key":"10.1016\/j.lungcan.2024.108024_b0255","first-page":"437","article-title":"Putative cancer stem cells in malignant pleural mesothelioma show resistance to cisplatin and pemetrexed","volume":"37","author":"Cortes-Dericks","year":"2010","journal-title":"Int. J. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2024.108024_b0260","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.lungcan.2013.11.011","article-title":"Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma","volume":"84","author":"Zucali","year":"2014","journal-title":"Lung Cancer"},{"issue":"10","key":"10.1016\/j.lungcan.2024.108024_b0265","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/S1470-2045(21)00404-6","article-title":"Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"22","author":"Pinto","year":"2021","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2024.108024_b0270","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/bjc.2014.312","article-title":"Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey","volume":"111","author":"Ceresoli","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lungcan.2024.108024_b0275","article-title":"Metformin Induces Apoptosis and Inhibits Notch1 in Malignant Pleural Mesothelioma Cells","volume":"8","author":"Rossini","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.lungcan.2024.108024_b0280","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10637-020-00944-z","article-title":"Phase 1 study of 2 high dose intensity schedules of the pan-Notch inhibitor crenigacestat (LY3039478) in combination with prednisone in patients with advanced or metastatic cancer","volume":"39","author":"Azaro","year":"2021","journal-title":"Invest. New Drugs"},{"issue":"8","key":"10.1016\/j.lungcan.2024.108024_b0285","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nrclinonc.2015.61","article-title":"Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update","volume":"12","author":"Takebe","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2024.108024_b0290","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13045-023-01439-z","article-title":"The Notch signaling pathway: a potential target for cancer immunotherapy","volume":"16","author":"Li","year":"2023","journal-title":"J. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2024.108024_b0295","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1742-4658.2012.08565.x","article-title":"Molecular mechanisms of the PRL phosphatases","volume":"280","author":"Rios","year":"2013","journal-title":"FEBS J."},{"issue":"16","key":"10.1016\/j.lungcan.2024.108024_b0300","doi-asserted-by":"crossref","first-page":"10339","DOI":"10.1074\/jbc.M708285200","article-title":"Translational control of C-terminal Src kinase (Csk) expression by PRL3 phosphatase","volume":"283","author":"Liang","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.lungcan.2024.108024_b0305","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1158\/0008-5472.CAN-06-3598","article-title":"PRL-3 down-regulates PTEN expression and signals through PI3K to promote epithelial-mesenchymal transition","volume":"67","author":"Wang","year":"2007","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.lungcan.2024.108024_b0310","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1365-2559.2009.03226.x","article-title":"Prognostic value of PRL-3 overexpression in early stages of colonic cancer","volume":"54","author":"Xing","year":"2009","journal-title":"Histopathology"},{"issue":"7","key":"10.1016\/j.lungcan.2024.108024_b0315","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1158\/0008-5472.CAN-14-0673","article-title":"Phosphatase PTP4A3 Promotes Triple-Negative Breast Cancer Growth and Predicts Poor Patient Survival","volume":"76","author":"den Hollander","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2024.108024_b0320","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1186\/1479-5876-11-309","article-title":"Phosphatase of regenerating liver-3 (PRL-3) is associated with metastasis and poor prognosis in gastric carcinoma","volume":"11","author":"Xing","year":"2013","journal-title":"J. Transl. Med."},{"issue":"2","key":"10.1016\/j.lungcan.2024.108024_b0325","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.3390\/ijms12021133","article-title":"Expression and clinical role of protein of regenerating liver (PRL) phosphatases in ovarian carcinoma","volume":"12","author":"Reich","year":"2011","journal-title":"Int. J. Mol. Sci."},{"issue":"14","key":"10.1016\/j.lungcan.2024.108024_b0330","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1002\/cncr.28668","article-title":"Independent oncogenic and therapeutic significance of phosphatase PRL-3 in FLT3-ITD-negative acute myeloid leukemia","volume":"120","author":"Qu","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2024.108024_b0335","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.717688","article-title":"PTP4A3 is a prognostic biomarker correlated with immune infiltrates in papillary renal cell carcinoma","volume":"12","author":"Song","year":"2021","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.lungcan.2024.108024_b0340","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/cas.13505","article-title":"Whole genome sequencing analysis for cancer genomics and precision medicine","volume":"109","author":"Nakagawa","year":"2018","journal-title":"Cancer Sci."},{"issue":"4","key":"10.1016\/j.lungcan.2024.108024_b0345","doi-asserted-by":"crossref","DOI":"10.3390\/genes15040396","article-title":"Comprehensive Analysis of Clinically Relevant Copy Number Alterations (CNAs) using a 523-gene next-generation sequencing panel and NxClinical software in solid tumors","volume":"15","author":"Gupta","year":"2024","journal-title":"Genes (Basel)"},{"issue":"24","key":"10.1016\/j.lungcan.2024.108024_b0350","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15245716","article-title":"Clinical next generation sequencing application in mesothelioma: finding a golden needle in the haystack","volume":"15","author":"Cerbone","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.lungcan.2024.108024_b0355","doi-asserted-by":"crossref","DOI":"10.3390\/jpm14040394","article-title":"BAP1 loss, nuclear grading, and nonepithelioid features in the diagnosis of mesothelioma in Italy: nevermore without the pathology report","volume":"14","author":"Rossi","year":"2024","journal-title":"J Pers Med"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500224005580?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500224005580?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T02:22:59Z","timestamp":1733278979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500224005580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":71,"alternative-id":["S0169500224005580"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2024.108024","relation":{},"ISSN":["0169-5002"],"issn-type":[{"type":"print","value":"0169-5002"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NOTCH and PTP4A3 alterations emerge as novel predictive biomarkers and potential therapeutic targets in pleural mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2024.108024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108024"}}